Connect with us

Technologies

COVID raises risk of stillbirth, new research finds. What to know about vaccines during pregnancy

Here’s what we know about COVID-19 boosters, fertility and more.

For the most up-to-date news and information about the coronavirus pandemic, visit the WHO and CDC websites.

In September, the US Centers for Disease Control and Prevention recommended “urgent action” be taken to get pregnant people, and those who want to be pregnant in the future, vaccinated against COVID-19. The alert was issued after mounting evidence demonstrated how COVID-19 affected the outcomes of pregnancy and the overall health of the pregnant person. As of mid-September, only 31% of pregnant people were vaccinated against COVID-19 — a much lower rate than the general US adult population — but they had a 70% increased risk of dying from symptomatic COVID-19 compared to people who weren’t pregnant.

Now, research is showing that pregnant people with COVID-19 have a higher risk of their baby being stillborn, according to a November report by the CDC. While the overall rate of stillbirths was low from March 2020 to September 2021, people who had COVID-19 during their delivery had a 1.26% chance of stillbirth, compared to people without COVID-19 at .64% — roughly double the risk. This risk was even higher, the CDC said, during the months the delta variant was circulating.

The CDC, along with other organizations that serve pregnant people such as the American College of Obstetrics and Gynecology and the Society for Maternal-Fetal Medicine have all issued recommendations that pregnant people get vaccinated against COVID-19. This is because research available during the pandemic shows that COVID-19 vaccines are safe for pregnant people, breastfeeding parents and people who may consider pregnancy in the future.

The World Health Organization says COVID-19 vaccines approved by the WHO (which include Pfizer, Moderna and Johnson & Johnson) can be taken by people who are on their period (menstruating), pregnant, planning to get pregnant and breastfeeding.

But advice for pregnant people trying to make decisions about vaccines hasn’t always been so strong. Pregnant people are often left out of medical studies, so when vaccines initially became available to protect against COVID-19, those who were pregnant were absent from the early studies on coronavirus shots. While the COVID-19 pandemic has shone some light on pregnant and breastfeeding people’s age-old status as “vulnerable,” the lack of data collected about pregnancy in the clinical trials of all three of the vaccines available in the US may have left you sifting through conflicting advice on how best to protect you and your child. As new data emerges and illustrates how pregnancy increases risk of COVID-19 disease for parents, which also puts their child at risk, here’s what we know about COVID-19 vaccines and boosters in pregnancy.

I’m pregnant. Should I get the COVID-19 vaccine?

The CDC made its official recommendation in August that, yes, pregnant people, breastfeeding people and those who want to be pregnant in the future should get a COVID-19 vaccine. The ACOG and SMFM also recommended COVID vaccines for pregnant people at the end of July after reports from “tens of thousands” demonstrated the safety of COVID-19 vaccines in pregnancy.

Other vaccines are recommended or offered during pregnancy. Some vaccines, for other diseases, aren’t recommended for pregnant people because they contain (very small amounts) of a live virus. None of the coronavirus vaccines available in the US use a live virus.

Do I need a booster if I’m fully vaccinated and pregnant?

Boosters are authorized for all adults in the US, including pregnant people (as long as you’re 18 years or older). You may get a shot at least six months after your second Pfizer or Moderna vaccine, or at least two months after your Johnson & Johnson shot, according to CDC guidance. You can get any COVID-19 vaccine available in the US as a booster if you prefer to switch brands for any reason.

Read more: How to choose a booster: What to know about mixing coronavirus vaccines

The CDC guidance for the general adult population leaves the decision on whether to boost up to the individual. However, pregnant people were actually eligible for boosters before the general public because pregnancy, or being recently pregnant, makes someone more susceptible to severe COVID-19. The ACOG, which gives guidance to pregnant individuals and their providers, recommends boosters for people who are fully vaccinated and pregnant or up to six weeks postpartum. The SMFM also recommends boosters for pregnant individuals at least six months after their second shot (or two months after, for people who received Johnson & Johnson’s vaccine).

What are the side effects of the vaccine for pregnant people?

Preliminary data on about 35,000 pregnant people who were vaccinated and volunteered information through the V-safe program shows that pregnant people have the same vaccine side effects as nonpregnant people — temporary injection pain in the arm, fatigue, headache, muscle aches and fever.

However, it’s important to note that fever from any cause has been associated with adverse pregnancy outcomes, and the CDC recommends pregnant people who experience fever after vaccination take acetaminophen to lower their body temperature.

Why are pregnant people at a high risk of COVID-19?

In May, CNET talked to Dr. Ella Speichinger, an OB-GYN at University of Missouri Health Care. She said it isn’t exactly known why pregnant people are at a higher risk, but that it may be because pregnant people’s immune systems are naturally depressed so their bodies don’t reject the growing fetus, or because pregnancy could alter the body’s way of mounting an immune response to COVID-19.

“I’ve had many patients who have had COVID while they were pregnant, and they’ve been just fine,” she said. “But there have definitely been severe cases where patients had to get delivered early because they could no longer oxygenate their fetus.”

In these cases, Speichinger said the patients usually improved after giving birth, but that it was delayed. It’s also impossible to know who will have a bad reaction to COVID-19 while pregnant.

“It’s really unclear who of the healthy pregnant cohorts is going to be the one that gets sick,” she said.

I’m skeptical of the vaccine. What are the risks of getting COVID-19 while pregnant?

Pregnant and recently pregnant people are at higher risk of severe illness from COVID-19, including death, according to the CDC, and they’re also at increased risk for preterm delivery (birth before 37 weeks) and other adverse pregnancy outcomes including stillbirth. Other health factors of the pregnant person, including a high BMI, diabetes or heart conditions, may elevate this risk, according to the SMFM.

Although there is information available now about how risky COVID-19 can be for pregnant people, that wasn’t necessarily the case at the beginning of the pandemic, and pregnant people were not highlighted specifically as “high risk.” Speichinger said that is likely because people who get pregnant are usually generally healthy and under age 40.

During what trimester should I get the vaccine?

Scientists who looked at people who got vaccinated earlier than 20 weeks pregnant didn’t find an increased risk of miscarriage compared to those who didn’t, according to a report from the V-safe pregnancy registry. Earlier data that was available reflected vaccination during the later stages of pregnancy.

Some people holding out on getting vaccinated during the first trimester may be due to the naturally high rate of miscarriage in the first three months, and patients being more cautious because of that. About 10% of known pregnancies end in miscarriage, according to the ACOG, but the risk also increases with age. About 80% of miscarriages happen in the first trimester.

“Most people feel concerned in the first trimester because there’s such a high risk of miscarriage in general,” Speichinger said. “Conflating the miscarriage with vaccine administration is what leads to vaccine hesitancy in the first trimester.”

Research shows that parents vaccinated during the third trimester of pregnancy may pass antibodies onto their newborns.

What if I’m breastfeeding?

“If a woman is uncomfortable doing it while pregnant, I absolutely think getting it while she’s breastfeeding is a good idea,” Speichinger said. “Because all of those antibodies can then cross through to the milk and protect baby while the mom is still producing those antibodies.”

There’s not enough data to show how long that protection lasts, but the CDC reports that breastfeeding people who have received an mRNA vaccine produce COVID-19 antibodies in their breast milk. In a small study on lactating health care workers who received a mRNA vaccine while breastfeeding, researchers from the University of Florida found that their breast milk had a “significant” amount of antibodies.

In its latest report, the CDC made a strong recommendation that breastfeeding people and those who were recently pregnant get a COVID-19 vaccine.

Does the vaccine type matter?

Moderna and Pfizer’s are mRNA vaccines, which use a new technology that delivers instructions to our immune systems on how to make protective proteins. Johnson & Johnson’s, the third vaccine available for emergency use in the US, uses viral vector technology by delivering a harmless virus into our bodies that triggers an immune response. Viral vector vaccines, notably the Ebola vaccine, have been studied in pregnant and breastfeeding people with no adverse effects found, according to the CDC.

The early research available now shows that mRNA vaccines are safe for pregnant women, and that miscarriage rates among women who received a COVID-19 vaccine are similar to miscarriage rates of women who didn’t get vaccinated. In a V-safe survey of 827 pregnant women who got a COVID-19 vaccine, about 14% experienced pregnancy loss — within the range that is naturally expected.

After the Food and Drug Administration lifted the pause that had been placed on Johnson & Johnson after reports of blood clots (the CDC identified 28 cases out of 8.7 million people vaccinated with Johnson & Johnson, the majority of them in women), the CDC issued a statement that women under age 50 should be aware of their increased risk of this still rare, but serious form of blood clots, and consider the other vaccines that don’t carry this risk. Given the demographic of the blood-clotting risk, Speichinger said her bias would steer her pregnant patients toward a Pfizer or Moderna vaccine.

“I still think the risk is exceedingly rare compared to the complications of COVID,” she said. “But if you had a choice, I would pick one of the other two.”

I want to be pregnant in the future. Will the COVID-19 vaccine make me infertile?

The fear people have regarding their fertility and vaccination isn’t exclusive to the COVID-19 vaccine. The specific fear about infertility and COVID-19 vaccines stems from a now-debunked post on Facebook that claimed the vaccine would make pregnant people’s bodies attack a protein needed for placenta formation in early pregnancy, because, it asserted, the spike protein in the COVID-19 vaccine is “similar.” Experts have disproved this, saying that not only do the two proteins have “almost nothing in common,” but even if they did, infection with COVID-19 would have the same outcome. There is no research to suggest people who have had COVID-19 will have a more difficult time getting pregnant, and many have since the beginning of the pandemic. If you’d like more information about COVID-19 vaccines and pregnancy, Dr. Danielle Jones, an OB-GYN who is also known as “Mama Doctor Jones” on TikTok, shared this video on YouTube debunking myths about COVID-19 vaccines and infertility, miscarriage and pregnancy.

The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.

Technologies

Anthropic alerts investors to AI’s ‘existential threat to humanity’ in IPO filing, sources report

Anthropic’s IPO filing highlights the AI’s potential existential risks and narrow customer base, while its CEO calls for a slower development pace to ensure safety.

Anthropic plans to warn speculative investors in its IPO prospectus that its AI models pose a “catastrophic or existential risk to humanity,” several reports said on Tuesday.

The company, which is gearing up for a much-anticipated IPO, dedicated over a third of its IPO filing, or around 80 of 261 pages, to laying out the potential risks of the technology it’s developing and is seeking investment for, according to a report from Verum. It only used 48 pages to discuss its actual business.

The five-year-old company, known for its frontier language model Claude, warned that AI can have “self-preserving behaviors,” including being able to “resist shutdown,” “conceal or manipulate information,” and carry out behaviors “resembling blackmail,” per the Verum report.

The company is pursuing a $2 trillion valuation when it goes public and reported in the filing that it made a net loss of $42 billion in 2025. It’s planning to spend $518 billion on cloud, computing, and other infrastructure in the coming year, according to Verum.

Anthropic also warned that its customer base is extremely narrow, with nearly a quarter of its revenue last year coming from just two clients, two people familiar with the filing told the Financial Times.

AI safety guardrails

Anthropic’s co-founder and CEO Dario Amodei has previously written various essays warning on the threats of AI, including saying the technology will cause “unusually painful” disruption to the job market.

In another recent essay, the CEO urged the AI industry to slow the pace of AI model development, with a three-step plan to reduce how quickly models get better without “sacrificing commercial advantage or the United States’ lead in AI.”

Those calls for a slowdown are somewhat of a “head scratcher” for the sector, to which the market has reacted “pretty resoundingly,” Dan Ives, partner and senior managing director at Yorkville Ives told CNBC earlier today.

“You need guardrails from a safety perspective, but the fact for Anthropic and OpenAI to slow down, if they slowed down, China would just accelerate and win, and I think that’s part of this quagmire that you’re seeing is that there’s some regulatory capture going on. There’s definitely a game of poker, but for Anthropic, they got to continue to put foot on the pedal.”

Ives added that while guardrails are essential, regulation could stifle innovation. That continues to be the “biggest concern within the U.S., which is why we’re in an F1 race,” he said.

Continue Reading

Technologies

U.S. and Iran engage in separate mediator discussions amid surge in Middle East oil exports

U.S. and Iranian officials held separate indirect talks mediated by Qatar as Middle East crude exports neared wartime highs, while Tehran awaits a U.S. response to its cease‑fire and sanctions‑relief proposal.

On Monday, American and Iranian representatives engaged in distinct indirect negotiations mediated by third parties, aiming to halt seven months of hostilities while Iran awaits Washington’s reply to an updated cease‑fire proposal and Middle Eastern oil shipments reach wartime peaks.

Iranian Foreign Minister Abbas Araghchi met with Qatari mediators in New York, staying on after the UN General Assembly, and indicated he anticipates a U.S. response by Tuesday. “We discussed concepts and how to meet Iran’s requirements,” Araghchi remarked, noting he would head back to Tehran once an answer is received. “When the Qataris have a reply, they know how to deliver it to us.”

The Iranian plan, initially unveiled during the sidelines of last week’s UN General Assembly, asks the United States to unfreeze Iranian assets, remove oil sanctions and lift the naval blockade of Iranian ports within four to five days, and to commence nuclear negotiations within a week. Tehran links any resumption of traffic through the Strait of Hormuz to the fulfillment of those conditions.

On Sunday, President Donald Trump dismissed the proposal as “unacceptable,” asserting that Iran seeks a rapid agreement due to economic strain. Speaking at the White House on Monday, Trump noted that U.S. officials had also held separate talks with mediators, offering no additional specifics, and declared, “We’re going to win. It’s going to happen fast.”

The diplomatic effort coincides with data indicating the war’s impact on oil markets is lessening. Middle Eastern crude exports have risen this month to near their highest point since the conflict started in February, according to Kpler. The firm noted in a Monday briefing that exports are “just under 80% of pre‑conflict levels.”

The Strait of Hormuz remains far from usual activity. Kpler’s real‑time monitoring recorded a flow of 10,591 kilobarrels per day through the strait on Saturday, compared with a prewar baseline of 17,133 kilobarrels per day.

The ongoing impasse is influencing U.S. fuel markets, where retail diesel prices linger close to a record $6.53 per gallon. The Trump administration is reconsidering an export ban, having recently distanced itself from an earlier iteration of the idea; Kpler estimates such a ban would retain about 1.2 million barrels per day domestically, potentially straining storage capacity.

Continue Reading

Technologies

Saudi Red Sea export rebound pushes oil prices down

Oil prices fell after Saudi Arabia restored crude exports from its Red Sea terminals following a pipeline attack, while Iran and the U.S. continue talks over the Strait of Hormuz.

Oil prices fell on Tuesday as Saudi Arabia’s crude exports from its Red Sea ports recovered from an attack on a key pipeline earlier this month. The decline reflects renewed flow from major loading points.

Satellite imagery confirmed a “major operational recovery” at the Yanbu and Muajjiz terminals, according to a Kpler note released on Tuesday. The data shows that 12.5 million barrels were loaded onto nine tankers at Yanbu between Saturday and Monday, restoring activity after a drone strike disrupted the East‑West pipeline earlier in the month.

Riyadh has brought the pipeline’s throughput back to roughly 3.5 million barrels per day, people familiar with the matter told The Wall Street Journal and Bloomberg News on Monday. The line’s maximum capacity is 7 million bpd, indicating that the current flow is about half of its peak.

Meanwhile, U.S. and Iranian officials spoke with mediators on Monday as they attempt anew to negotiate a deal to end the seven‑month conflict. Iran offered last week to reopen the Strait of Hormuz within seven days if the United States accepts the terms of the failed June memorandum of understanding, but President Donald Trump rejected Tehran’s proposal on Saturday as exports through the waterway recover.

Oil flows through Hormuz have averaged 13.2 million barrels per day over the past week, according to Kpler data—about 77 % of the 17 million bpd that moved through the strait before the U.S.–Iran war. The U.S. military continues to protect tankers from Gulf allies and maintains a blockade on Iranian exports.

Continue Reading

Trending

Copyright © Verum World Media